William Bradley Purchases 68,493 Shares of Fractyl Health (NASDAQ:GUTS) Stock

Fractyl Health, Inc. (NASDAQ:GUTS) Director William Bradley bought 68,493 shares of the company’s stock in a transaction on Wednesday, June 10th. The shares were bought at an average cost of $0.73 per share, for a total transaction of $49,999.89. Following the transaction, the director owned 84,622 shares in the company, valued at $61,774.06. The trade was a 424.66% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link.

Fractyl Health Stock Up 17.4%

NASDAQ:GUTS opened at $0.85 on Friday. The company has a market cap of $134.85 million, a PE ratio of -0.66 and a beta of 2.34. Fractyl Health, Inc. has a twelve month low of $0.38 and a twelve month high of $2.45. The company has a current ratio of 4.28, a quick ratio of 4.28 and a debt-to-equity ratio of 1.41. The company’s 50 day moving average is $0.69 and its two-hundred day moving average is $1.07.

Fractyl Health (NASDAQ:GUTS) last released its earnings results on Tuesday, May 12th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.23. Analysts anticipate that Fractyl Health, Inc. will post -0.6 EPS for the current year.

Institutional Trading of Fractyl Health

Several institutional investors and hedge funds have recently bought and sold shares of the business. Nantahala Capital Management LLC acquired a new stake in Fractyl Health during the 3rd quarter valued at approximately $19,298,000. 683 Capital Management LLC lifted its stake in Fractyl Health by 30.1% during the 4th quarter. 683 Capital Management LLC now owns 6,047,620 shares of the company’s stock valued at $13,305,000 after acquiring an additional 1,397,620 shares during the period. Marshall Wace LLP lifted its stake in Fractyl Health by 234.9% during the 4th quarter. Marshall Wace LLP now owns 5,926,745 shares of the company’s stock valued at $13,039,000 after acquiring an additional 4,156,969 shares during the period. Pale Fire Capital SE lifted its stake in Fractyl Health by 84.5% during the 1st quarter. Pale Fire Capital SE now owns 5,921,045 shares of the company’s stock valued at $2,711,000 after acquiring an additional 2,711,103 shares during the period. Finally, Alyeska Investment Group L.P. acquired a new stake in Fractyl Health during the 3rd quarter valued at approximately $8,981,000.

Analyst Ratings Changes

Several research firms have weighed in on GUTS. HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of Fractyl Health in a research report on Thursday, June 4th. Canaccord Genuity Group reissued a “buy” rating and set a $8.00 target price on shares of Fractyl Health in a research report on Thursday, March 26th. Wall Street Zen raised shares of Fractyl Health from a “strong sell” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Fractyl Health in a research report on Tuesday, May 12th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $5.40.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.